Home
Conditions
Immunoproliferative Disorders

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,003 public trials 2,033 recruiting studies

Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients

NCT01561833

Conditions: Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations: Yale Cancer Center New Haven, Connecticut, United States

View Trial Details

Completed

Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia

NCT01869777

Conditions: Acute Undifferentiated Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), +27 more
Locations: Comprehensive Cancer Center of Wake Forest University Winston-Salem, North Carolina, United States

View Trial Details

Completed

UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT02222688

Conditions: Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +14 more
Locations: UCSD Moores Cancer Center La Jolla, California, United States

View Trial Details

Completed

Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma

NCT00002715

Conditions: Hemic and Lymphatic Diseases, Hodgkin Disease, Immune System Diseases, +6 more
Locations: Stanford Cancer Center at Stanford University Medical Center Stanford, California, United States

View Trial Details

Completed

A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients

NCT02867566

Conditions: Diffuse, Large B-Cell, Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations: Institute of Hematology; Chinese Academy of Medical Sciences Tianjin, China

View Trial Details

Completed

IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT

NCT01885897

Conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Bone Marrow Diseases, +28 more
Locations: Masonic Cancer Center, University of Minnesota Minneapolis, Minnesota, United States

Washington University St Louis, Missouri, United States

University of Pennsylvania Philadelphia, Pennsylvania, United States

View Trial Details

Completed

Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma

NCT01542918

Conditions: Disease Attributes, Eye Neoplasms, Hemic and Lymphatic Diseases, +13 more
Locations: University of California, San Francisco San Francisco, California, United States

View Trial Details

Completed

BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)

NCT01403948

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
Locations: INS Paoli-Calmettes Marseille, France

HOP Lyon Sud Pierre-Bénite, France

Charité - Universitätsmedizin Berlin Berlin, Germany

Universitätsklinikum Carl Gustav Carus Dresden Dresden, Germany

View Trial Details

Completed

Programmed Environmental Illumination (PEI) of Hospital Rooms to Prevent/Reduce Cancer-Related Fatigue

NCT03198754

Conditions: Behavior, Behavioral Symptoms, Blood Protein Disorders, +19 more
Locations: Icahn School of Medicine at Mount Sinai New York, United States

View Trial Details

Completed

Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916

NCT02064387

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations: GSK Investigational Site Boston, Massachusetts, United States

GSK Investigational Site New York, United States

GSK Investigational Site Chapel Hill, North Carolina, United States

GSK Investigational Site Philadelphia, Pennsylvania, United States

View Trial Details

Immunoproliferative Disorders

Immunoproliferative Disorders trial results

Related conditions